Phase II trial of interleukin-12 (NSC #672423, IND #6798) followed by interferon alfa-2B in patients with metastatic malignant melanoma
Phase of Trial: Phase II
Latest Information Update: 19 Dec 2012
At a glance
- Drugs Interferon alpha (Primary) ; Interleukin-12 (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 01 Apr 2011 Actual end date changed from Jan 2010 to Feb 2008 as reported by ClinicalTrials.gov.
- 01 Apr 2011 Actual initiation date changed from Jun 2002 to Sep 2001 as reported by ClinicalTrials.gov.